BACKGROUND: People living with HIV are at risk of increased myocardial infarction (MI). Cumulative HIV viral load (VL) has been proposed as a better measure of HIV inflammation than other measures of VL, like baseline VL, but its associations with MI are not known. METHODS: The multisite Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) cohort includes clinical data and centrally adjudicated MI with distinction between atheroembolic MI (type 1) and MI related to supply-demand mismatch (type 2). We examined CNICS participants who were not on antiretroviral therapy (ART) at enrollment. Cumulative VL (copy-days of virus) from 6 months after enrollment was estimated with a time-weighted sum using the trapezoidal rule. We modeled associations of cumulative and baseline VL with MI by type using marginal structural Cox models. We contrasted the 75% percentile of the VL distribution with the 25% percentile. RESULTS: Among 11,324 participants, 218 MIs occurred between 1996 and 2016. Higher cumulative VL was associated with risk of all MI (hazard ratio [HR] = 1.72; 95% confidence interval [CI] = 1.26, 2.36), type 1 MI (HR = 1.23; 95% CI = 0.78, 1.96), and type 2 MI (HR = 2.52; 95% CI = 1.74, 3.66). While off ART, cumulative VL had a stronger association with type 1 MI (HR = 2.13; 95% CI = 1.15, 3.94) than type 2 MI (HR = 1.25; 95% CI = 0.70, 2.25). Baseline VL was associated with all MI (HR = 1.60; 95% CI = 1.28, 2.01), type 1 MI (HR = 1.73; 95% CI = 1.26, 2.38), and type 2 MI (HR = 1.51; 95% CI = 1.10, 2.08). CONCLUSIONS: Higher cumulative and baseline VL is associated with all MI, with a particularly strong association between cumulative VL and type 2 MI.
BACKGROUND:People living with HIV are at risk of increased myocardial infarction (MI). Cumulative HIV viral load (VL) has been proposed as a better measure of HIV inflammation than other measures of VL, like baseline VL, but its associations with MI are not known. METHODS: The multisite Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) cohort includes clinical data and centrally adjudicated MI with distinction between atheroembolic MI (type 1) and MI related to supply-demand mismatch (type 2). We examined CNICS participants who were not on antiretroviral therapy (ART) at enrollment. Cumulative VL (copy-days of virus) from 6 months after enrollment was estimated with a time-weighted sum using the trapezoidal rule. We modeled associations of cumulative and baseline VL with MI by type using marginal structural Cox models. We contrasted the 75% percentile of the VL distribution with the 25% percentile. RESULTS: Among 11,324 participants, 218 MIs occurred between 1996 and 2016. Higher cumulative VL was associated with risk of all MI (hazard ratio [HR] = 1.72; 95% confidence interval [CI] = 1.26, 2.36), type 1 MI (HR = 1.23; 95% CI = 0.78, 1.96), and type 2 MI (HR = 2.52; 95% CI = 1.74, 3.66). While off ART, cumulative VL had a stronger association with type 1 MI (HR = 2.13; 95% CI = 1.15, 3.94) than type 2 MI (HR = 1.25; 95% CI = 0.70, 2.25). Baseline VL was associated with all MI (HR = 1.60; 95% CI = 1.28, 2.01), type 1 MI (HR = 1.73; 95% CI = 1.26, 2.38), and type 2 MI (HR = 1.51; 95% CI = 1.10, 2.08). CONCLUSIONS: Higher cumulative and baseline VL is associated with all MI, with a particularly strong association between cumulative VL and type 2 MI.
Authors: Jim Young; Yongling Xiao; Erica E M Moodie; Michal Abrahamowicz; Marina B Klein; Enos Bernasconi; Patrick Schmid; Alexandra Calmy; Matthias Cavassini; Alexia Cusini; Rainer Weber; Heiner C Bucher Journal: J Acquir Immune Defic Syndr Date: 2015-08-01 Impact factor: 3.731
Authors: Anne-Lise Paisible; Chung-Chou H Chang; Kaku A So-Armah; Adeel A Butt; David A Leaf; Matthew Budoff; David Rimland; Roger Bedimo; Matthew B Goetz; Maria C Rodriguez-Barradas; Heidi M Crane; Cynthia L Gibert; Sheldon T Brown; Hilary A Tindle; Alberta L Warner; Charles Alcorn; Melissa Skanderson; Amy C Justice; Matthew S Freiberg Journal: J Acquir Immune Defic Syndr Date: 2015-02-01 Impact factor: 3.731
Authors: Michael J Mugavero; Sonia Napravnik; Stephen R Cole; Joseph J Eron; Bryan Lau; Heidi M Crane; Mari M Kitahata; James H Willig; Richard D Moore; Steven G Deeks; Michael S Saag Journal: Clin Infect Dis Date: 2011-09-02 Impact factor: 9.079
Authors: Stephen R Cole; Sonia Napravnik; Michael J Mugavero; Bryan Lau; Joseph J Eron; Michael S Saag Journal: Am J Epidemiol Date: 2009-12-09 Impact factor: 4.897
Authors: Matthew S Freiberg; Chung-Chou H Chang; Lewis H Kuller; Melissa Skanderson; Elliott Lowy; Kevin L Kraemer; Adeel A Butt; Matthew Bidwell Goetz; David Leaf; Kris Ann Oursler; David Rimland; Maria Rodriguez Barradas; Sheldon Brown; Cynthia Gibert; Kathy McGinnis; Kristina Crothers; Jason Sico; Heidi Crane; Alberta Warner; Stephen Gottlieb; John Gottdiener; Russell P Tracy; Matthew Budoff; Courtney Watson; Kaku A Armah; Donna Doebler; Kendall Bryant; Amy C Justice Journal: JAMA Intern Med Date: 2013-04-22 Impact factor: 21.873
Authors: Caroline A Sabin; Peter Reiss; Lene Ryom; Andrew N Phillips; Rainer Weber; Matthew Law; Eric Fontas; Amanda Mocroft; Stephane de Wit; Colette Smith; Francois Dabis; Antonella d'Arminio Monforte; Wafaa El-Sadr; Jens D Lundgren Journal: BMC Med Date: 2016-03-31 Impact factor: 8.775
Authors: Ashley D Olson; A Sarah Walker; Amitabh B Suthar; Caroline Sabin; Heiner C Bucher; Inma Jarrin; Santiago Moreno; Santiago Perez-Hoyos; Kholoud Porter; Deborah Ford Journal: J Acquir Immune Defic Syndr Date: 2016-09-01 Impact factor: 3.731
Authors: Brandon R Luu; Robin M Nance; Joseph A C Delaney; Stephanie A Ruderman; Susan R Heckbert; Matthew J Budoff; William C Mathews; Richard D Moore; Matthew J Feinstein; Greer A Burkholder; Michael J Mugavero; Joseph J Eron; Michael S Saag; Mari M Kitahata; Heidi M Crane; Bridget M Whitney Journal: J Acquir Immune Defic Syndr Date: 2022-05-01 Impact factor: 3.771
Authors: James H Stein; Noah Kime; Claudia E Korcarz; Heather Ribaudo; Judith S Currier; Joseph C Delaney Journal: Arterioscler Thromb Vasc Biol Date: 2020-12-17 Impact factor: 8.311
Authors: Barbara N Harding; Tigran Avoundjian; Susan R Heckbert; Bridget M Whitney; Robin M Nance; Stephanie A Ruderman; Rizwan Kalani; David L Tirschwell; Emily L Ho; Kyra J Becker; Joseph Zunt; Felicia Chow; Andrew Huffer; W Christopher Mathews; Joseph Eron; Richard D Moore; Christina M Marra; Greer Burkholder; Michael S Saag; Mari M Kitahata; Heidi M Crane; Joseph C Delaney Journal: Epidemiology Date: 2021-05-01 Impact factor: 4.860
Authors: Ana R Pascom; Rosana Egg Pinho; Fernanda Rick; Nazle Mc Veras; Filipe de Barros Perini; Mariana V Meireles; Gerson F Pereira; Adele S Benzaken; Vivian I Avelino-Silva Journal: J Int AIDS Soc Date: 2019-11 Impact factor: 5.396